SUITE 2000 - 1066 WEST HASTINGS ST. VANCOUVER, B.C. CANADA V6E 3X2
Telephone (604) 806-6110 www.enwave.net Facsimile (604) 806-6112
EnWave Corporation Hires Vancouver Investor Relations Firm
Vancouver, British Columbia, November 01, 2006. TSXV: ENW; Frankfurt: E4U
EnWave Corporation (“EnWave” or “the Company”) has engaged the consulting services of Cypress
Point Capital (“Cypress”) of Vancouver, B.C. to undertake investor relations activities for the company.
Cypress will assist with the coordination and dissemination of company news and information to the
public, to the shareholders of the Company, and to brokers and brokerage houses.
Cypress is a full-service investor relations business supplying communications consulting, analytical
consulting, media relations, editorial services, shareholder identification and market analysis. In addition,
Cypress possesses a number of proprietary tools for managing a large catalogue of investors, portfolio
managers and analysts specifically covering growth-stage biotech companies. Tim Durance, President and
CEO of EnWave, stated that “the appointment of Cypress Point Capital to assist the company with our
investor relations activities is a continuation of our strategy to build a broader investor base for EnWave.
Cypress has a solid reputation with a large number of potential shareholders, and should be able to help
EnWave reach this community following the completion of our new biotechnology business plan.”
EnWave will continue to list on the Frankfurt stock exchange for the foreseeable future, but the work
performed by the previously announced European consulting company will be taken over by Cypress.
The agreement with Cypress has a term of 16 months from this date, and the Company has granted
250,000 incentive stock options to Cypress at an exercise price of $0.30 for a period of two years, subject
to regulatory approvals and applicable securities laws under the terms of the stock option agreement as set
forth by the Company. The options will have a four month hold as required by TSX Venture Exchange
policies and securities law, and will vest in equal parts every four months, with the first tranche vesting at
the end of the hold period. The grant is subject to regulatory approval. No cash compensation is
contemplated other than pre-approved expenses. Except for the foregoing, Cypress does not hold any
interest, directly or indirectly, in EnWave or its securities, or any right or intent to acquire such an
EnWave is a spin-off company from the University of British Columbia. Originally created to
commercialize our Vacuum Microwave (“VM”) food dehydration technology in 1997, we have
discovered that a refinement of this technology, Radiant-Energy Vacuum, or “REV”, can be used to form
biological materials for medical applications. Through our collaboration with researchers at UBC and
elsewhere, we are developing a number of promising new applications in the fields of tissue engineering
and drug delivery.
Dr. Tim Durance
President and C.E.O.
For further information: Dr. Tim Durance, President, (604) 806-6110, fax (604) 806-6112
Page 1 of 2
Safe Harbour for Forward-Looking Information Statements: This release may contain forward-looking information
based on management's expectations, estimates and projections. All statements that address expectations or
projections about the future, including statements about the Company's strategy for growth, product development,
market position, expected expenditures and financial results are forward-looking statements. Forward looking
statements in this press release include: “ should be able to help” and “foreseeable future”. These statements are
not guarantees of future performance and involve a number of risks, uncertainties and assumptions: there is no
guarantee that the Company’s REV technology can or will be used to develop materials for the tissue engineering or
drug delivery markets; even if the Company’s REV technology can be used as described in this news release, there
is no guarantee that such use will result in orders for the Company’s REV technology; changes in technology may
render the Company’s equipment offerings obsolete; changes in the laws, regulations, policies and economic
conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company
does business or intends to do business; competitive pressures; successful integration of structural changes,
including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and
development of new products, including regulatory approval and market acceptance; and seasonality of sales in
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this news release.
Page 2 of 2